Ascil Biopharm

Ascil Biopharm is a Barcelona-based biotech company with a dual business model: developing its own innovative drug delivery systems and providing contract development and manufacturing (CDMO) services. The company specializes in complex formulations for systemic and locoregional delivery, with a clinical-stage pipeline and a portfolio of proprietary medical devices. Its strategy leverages European grant funding and aims to address unmet medical needs through enhanced drug efficacy, safety, and patient convenience.

Ascil Biopharm's core platform combines proprietary controlled-release formulations for systemic and locoregional delivery with precision-engineered medical devices for injectable administration, all supported by integrated GMP manufacturing capabilities.

Ascil competes with established somatostatin analog marketers (Novartis, Ipsen) on formulation innovation and with global CDMOs (Lonza, Catalent) on niche expertise in complex parenteral delivery. Its differentiation lies in the integrated combination of novel formulations with proprietary, patient-centric injection devices.